Navigation Links
Viveve-Sponsored Research Accepted for Presentation at Two Prestigious International Conferences
Date:7/14/2010

PALO ALTO, Calif., July 14 /PRNewswire/ -- Viveve, Inc., a women's sexual health company that has developed a medical device and procedure to treat vaginal laxity, recently received notification that its sponsored abstracts were accepted for the 2010 International Meetings for the International Continence Society (ICS), International Urogynocological Association (IUGA), being held as a joint meeting in 2010, and the International Society of Sexual Medicine (ISSM). The subject of the abstracts focused on research with women and OB/GYNs regarding patients' sexual health, attitudes on vaginal laxity after childbirth, and the lack of conversation about these topics between a patient and her doctor.

"I believe the fact that these two abstracts were both accepted at such highly regarded conferences on women's health and women's sexual health demonstrate the growing interest and attention worldwide to these very important topics," said Dr. Leah Millheiser, OB/GYN and Director of the Women's Sexual Health Program at Stanford University and first author on both abstract submissions.

The abstract submitted and accepted for ICS/IUGA titled "A Cross-Sectional Survey to Assess the Prevalence and Symptoms Associated with Laxity of the Vaginal Introitus" reports on findings from qualitative and quantitative research conducted with women in the United States 25-55 years old, who have delivered at least one child vaginally. This abstract was accepted as a Podium Presentation at the Joint Meeting of ICS/IUGA which will take place in Toronto, Canada, August 23-27, 2010.

The abstract submitted and accepted for ISSM titled "Cross-Sectional Survey of Sexual Health and Vaginal Laxity Following Vaginal Delivery" reports on findings in two independent quantitative research studies, one study with 421 women in the U.S. 25-55 years old who've delivered at least one child vaginally; the other study with 524 OB/GYNs practicing in the United States. This abstract was accepted as an Unmoderated Poster Presentation at the 14th World Meeting of the ISSM, which will take place in Seoul, Korea, September 26-30, 2010.

"We are very pleased ICS, IUGA and ISSM are acknowledging the importance of this research to their memberships," says Kerry Pope, CEO of Viveve. "We will continue to share our knowledge about vaginal laxity and women's desire to communicate its impact on their sexual health to their OB/GYNs."

For more information on the ISSM meeting, please visit: http://www.issm2010.info/site/

For more information on the joint ICS/IUGA meeting, please visit: www.ics-iuga.com

To review the abstracts, please visit: http://www.viveve.com/clinical/publications/

About Viveve™

Viveve is a privately held women's sexual health company based in Palo Alto, California. The Viveve System is a medical device used for the nonsurgical procedure of post-birth laxity of the vaginal introitus, a medically recognized quality of life condition. The Viveve system received a general 510(k) clearance from FDA in 2008.

The company's Series A financing was led by GBS Venture Partners and 5AM Ventures. For more information, visit the Viveve Web site at www.viveve.com or phone 650-321-3332.


'/>"/>
SOURCE Viveve
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
3. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
4. Researchers at Cleveland Clinic Identify Site of Dysfunction in HDL, Carrier of Good Cholesterol
5. Video: New Research Discovers Independent Brain Networks Control Human Walking
6. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
7. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
8. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
9. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
10. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
11. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), ... company,s second affiliate in Latin America . ... ... Colombia ... ...
(Date:6/23/2016)... 23, 2016  Experian Health, the healthcare ... the patient payment and care experience, today ... products and services that will enhance the ... offerings. These award-winning solutions will enable healthcare ... compliant in an ever-changing environment and redefine ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension ... that it will receive two significant new grants to support its work to ... its 25th anniversary by recognizing patients, medical professionals and scientists for their work ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be ...
(Date:6/24/2016)... ... 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ... raise to $12 an hour by 2020 and then adjusting it yearly to increase at ... the minimum wage, assure the wage floor does not erode again, and make future increases ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its ... Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding ... Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, we ...
Breaking Medicine News(10 mins):